Q2 Earnings Estimate for CG Oncology Issued By HC Wainwright

Key Points

• HC Wainwright forecasts CG Oncology will post a $0.93-per-share loss in Q2 2027 and a $0.82-per-share loss in Q4 2027. The firm maintains a Buy rating and a $100 price target.
• CG Oncology’s latest reported quarter beat expectations: its loss was $0.64 per share versus an estimated $0.83, while revenue of $1.6 million topped the $0.55 million forecast.
• Analyst sentiment is broadly positive, with a MarketBeat consensus rating of Moderate Buy and an average price target of $87.50; 8 analysts rate the stock Buy, 1 Hold, and 1 Sell.

CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Investment analysts at HC Wainwright issued their Q2 2027 EPS estimates for CG Oncology in a report issued on Friday, November 6th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of ($0.93) per share for the quarter. HC Wainwright has a "Buy" rating and a $100.00 price target on the stock. The consensus estimate for CG Oncology's current full-year earnings is ($3.31) per share. HC Wainwright also issued estimates for CG Oncology's Q4 2027 earnings at ($0.82) EPS.

Other analysts have also issued research reports about the company. Royal Bank Of Canada cut their price objective on CG Oncology from $81.00 to $79.00 and set an "outperform" rating for the company in a report on Friday, August 7th. Piper Sandler increased their target price on CG Oncology from $82.00 to $85.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Truist Financial raised their target price on CG Oncology from $82.00 to $85.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Weiss Ratings restated a "sell (d-)" rating on shares of CG Oncology in a research note on Thursday, October 15th. Finally, Wall Street Zen raised shares of CG Oncology from a "strong sell" rating to a "sell" rating in a research report on Saturday. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $87.50.

CG Oncology Stock Performance

CGON opened at $75.99 on Monday. The company's 50-day simple moving average is $68.23 and its two-hundred day simple moving average is $66.09. The stock has a market capitalization of $6.74 billion, a P/E ratio of -27.53 and a beta of 0.35. CG Oncology has a 52-week low of $35.80 and a 52-week high of $80.97.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.19. The company had revenue of $1.60 million for the quarter, compared to analysts' expectations of $0.55 million. CG Oncology had a negative return on equity of 24.79% and a negative net margin of 3,851.09%.

Insider Activity

In related news, Director Leonard E. Post sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $62.06, for a total transaction of $62,060.00. Following the completion of the transaction, the director directly owned 1,000 shares in the company, valued at approximately $62,060. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 3,000 shares of company stock worth $209,580. Insiders own 4.80% of the company's stock.

Institutional Investors Weigh In On CG Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of CG Oncology in the second quarter worth about $444,509,000. Seven Fleet Capital Management LP grew its position in shares of CG Oncology by 24.5% during the second quarter. Seven Fleet Capital Management LP now owns 1,886,236 shares of the company's stock worth $134,017,000 after purchasing an additional 371,085 shares in the last quarter. Bank of America Corp DE grew its position in shares of CG Oncology by 21.8% during the first quarter. Bank of America Corp DE now owns 1,449,364 shares of the company's stock worth $98,093,000 after purchasing an additional 259,311 shares in the last quarter. EcoR1 Capital LLC raised its stake in CG Oncology by 3.5% during the 1st quarter. EcoR1 Capital LLC now owns 1,102,000 shares of the company's stock valued at $74,583,000 after purchasing an additional 37,200 shares during the period. Finally, Jefferies Financial Group Inc. raised its position in shares of CG Oncology by 8.5% during the third quarter. Jefferies Financial Group Inc. now owns 835,342 shares of the company's stock valued at $59,217,000 after buying an additional 65,395 shares during the last quarter. Institutional investors own 26.56% of the company's stock.

More CG Oncology News

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: CG Oncology reported a third-quarter loss of $0.64 per share, narrower than analysts’ estimates of about $0.83–$0.86 per share. Zacks earnings report
• Positive Sentiment: Revenue was $1.6 million, above the approximately $0.55 million analysts expected, further supporting the favorable market reaction. CG Oncology Gains on Q3 Results
• Neutral Sentiment: The quarterly loss widened from $0.57 per share a year earlier to $0.64, despite beating current estimates. Investors should weigh that ongoing loss against the earnings and revenue surprises. Zacks earnings report

About CG Oncology

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company's research centers on therapies delivered directly into the bladder.

Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

CG Oncology has no approved commercial products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.